Forest Laboratories, Inc. Files Additional Lawsuit against First Time US Generics LLC for Infringement of SAVELLA® Patents
October 02 2013 - 4:28PM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories
Holdings, Ltd. (collectively, “Forest”) announced that Forest and
Royalty Pharma Collection Trust (“Royalty Pharma”) have jointly
filed an additional lawsuit in the U.S. District Court for the
District of Delaware against First Time US Generics LLC (“First
Time”) for infringement of U.S. Patent No. 6,602,911 (“the ‘911
patent”), U.S. Patent No. 7,888,342 (“the ‘342 patent”), and U.S.
Patent No. 7,994,220 (“the ‘220 patent), which relate to Forest’s
SAVELLA® product. Forest licenses the ‘911 patent, the ‘342 patent,
and the ‘220 patent from Royalty Pharma. The ‘911 patent expires in
January 2023, the ‘342 patent expires in November 2021, and the
‘220 patent expires in September 2029.
Forest and Royalty Pharma received notification from First Time
that it has filed an Abbreviated New Drug Application with
Paragraph IV certifications seeking approval to market generic
versions of SAVELLA before the expiration of the ‘911 patent, the
‘342 patent, and the ‘220 patent. This lawsuit was commenced before
the expiration of forty-five days from the date of receipt of First
Time’s notification letter.
About Forest
Laboratories
Forest Laboratories' (NYSE:FRX) longstanding global partnerships
and track record developing and marketing pharmaceutical products
in the United States have yielded its well-established central
nervous system and cardiovascular franchises and innovations in
anti-infective, respiratory, gastrointestinal and pain management
medicine. Forest’s pipeline, the most robust in its history,
includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in
New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Forest Laboratories, Inc.Frank J. Murdolo, 1-212-224-6714Vice
President - Investor Relationsmedia.relations@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024